Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure

Inclusion Criteria: * Male or female cardiac recipients over 18 years old * First or second heart transplant, more than one year following surgery * Patients with renal failure assessed by cGFR 30 to 60 ml/min/1,73m² calculated by MDRD4 formula * Patients volunteer to participate in the study, with a written informed consent signed * Affiliation to a national health insurance program Exclusion Criteria: * Current CNI-free immunosuppressive regimen * Patients currently or previously treated with a mTOR inhibitor any time prior randomization * Patients who are recipients for a multiple solid organ transplant * Treated acute rejection episode within three months prior randomization * Congestive heart failure (NYHA class III or IV) and/or VEF \< 30 % and/or patient waiting for a re-transplantation * Scheduled surgical intervention * Platelet count \< 50 G/l * Severe hepatic insufficiency (SGPT and/or SGOT \> 3N) * Major lipidic profile abnormalities (total cholesterol \> 3g/l and/or TG \> 5g/l) * Proteinuria/creatinuria \> 0,08 g/mmol * Severe renal failure attested by cGFR \< 30 ml/min/1.73m² (MDRD4) * History of Hypersensitivity to everolimus, sirolimus or excipients * History of Hypersensitivity to macrolides * Pregnancy and breast feeding * Childbearing age women without efficient contraception * Law protected patients * Patients in emergency unable to express their consent * History of Hypersensitivity to cyclosporine or St-John's wort, stiripentol, bosentan, rosuvastatin * History of Hypersensitivity to tacrolimus, macrolides or excipients * History of Hypersensitivity to azathioprine * History of Hypersensitivity to mycophénolate mofetil or excipients